Published online 2015 July 1.

A Longitudinal Study of Adherence to the Mediterranean Dietary Pattern and Metabolic Syndrome in a Non-Mediterranean Population

Parvin Mirmiran¹; Nazanin Moslehi¹; Hessameddin Mahmoudof²; Mahbubeh Sadeghi¹; Fereidoun Azizi^{3,*}

1 Nutrition and Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

³Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

*Corresponding author: Fereidoun Azizi, Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran. Tel: +98-2122432500, Fax: +98-2122416264, E-mail: azizi@endocrine.ac.ir

Received: December 15, 2014; Revised: March 9, 2015; Accepted: May 1, 2015

Background: Adherence to the Mediterranean diet (MedDiet) has been proposed to reduce the risk of metabolic syndrome (MetS), but the association of the diet on MetS in non-Mediterranean populations remains unclear.

Objectives: The aim of this study was to investigate whether adherence to the MedDiet is related to the incident MetS and its components during a 3-year follow-up among Iranian adults.

Patients and Methods: Longitudinal associations between the MedDiet and MetS components were investigated on 2241 adults, aged 18-74 years, without type 2 diabetes selected from participants of the Tehran lipid and glucose study (TLGS). The association between the MedDiet and MetS incidence was also examined in 1661 participants, free of Mets at baseline, Adherence to the MedDiet was assessed using the traditional Mediterranean diet score (MDS) and a recently posteriori adaptation of the MDS of Sofi et al. (Sofi-MDS). MetS was defined according to the recent interim consensus.

Results: After adjusting for potential confounders, neither higher MDS nor higher Sofi-MDS were significantly associated with the mean values of MetS components and the risk of metabolic abnormalities incidence after 3 years follow-up. During the 3 years of follow-up, 246 developed MetS were identified. In multivariable model, the adjusted odds ratio (OR) of developing MetS did not differ significantly in participants with the highest tertile of the MDS (OR (95% CI): 0.88 (0.62 - 1.23)) or sofi-MDS (OR (95% CI):1.12 (0.77 - 1.62)) compared to those in the lowest tertiles.

Conclusions: Adherence to the MedDiet, according to MDS and Sofi-MDS, may not predict MetS components and MetS incidence after 3 years of follow-up in Iranian adult populations.

Keywords: Metabolic Syndrome; Mediterranean Diet; Metabolic Syndrome Components

1. Background

Metabolic syndrome (MetS) has become a major public health concern worldwide because of its associations with increased risk of type 2 diabetes (T2DM), cardiovascular morbidity and mortality and all-cause of mortality (1, 2). MetS prevalence is increasing rapidly due to urbanization and its consequences on life styles and dietary food habits (1, 2). The Mediterranean diet (MedDiet), as a model of healthy pattern, has been suggested to play a beneficial role in the prevention of cardiovascular disease, cancer, T2DM and all-cause mortality (3, 4). Most previous studies reported the possible protective effect of adherence to the MedDiet on MetS prevalence and its progression (5, 6); however, most investigations had preliminary cross-sectional designs (5, 6), and only three studies investigated prospectively the association between adherence to the MedDiet and development of MetS (7-9). In addition, most current knowledge on the influence of the

MedDiet on the risk of MetS comes from studies conducted among Mediterranean populations and therefore the benefits observed could be attributed to other potential confounders such as genetic and environmental factors (10). Furthermore, studies investigating the association between the pattern and each individual MetS components provided inconsistent findings (7-9, 11, 12). It is important to assess the association between adherence to the MedDiet and health outcomes in non-Mediterranean populations, because there is an interest in encouraging people with different cultures to adopt the MedDiet for primary and secondary prevention of chronic diseases.

2. Objectives

Considering the high prevalence and incident MetS in Iranian population (13, 14), we aimed to prospectively ex-

Copyright @ 2015, Research Institute For Endocrine Sciences and Iran Endocrine Society. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

amine the relation of adherence to the MedDiet with 1) mean values of MetS components 2) incidence of abnormalities in each MetS component and 3) MetS incidence in non-diabetic Iranian populations after 3 years of follow-up using two different the MedDiet scores.

3. Patients and Methods

The Tehran lipid and glucose study (TLGS) is an ongoing urban-population based prospective study aimed at identifying and preventing non-communicable diseases in district No. 13 of Tehran, the capital city of Iran. The initial TLGS study population consisted of 15005 (women and men, aged \geq 3 years), recruited during 1999 - 2001. Participants are evaluated every 3 years to update healthrelated data and identify newly developed diseases (15, 16). The study was approved by the ethics committee of the Research Institute for endocrine sciences of Shahid Beheshti university of medical sciences and written informed consent was obtained from each participant.

For the current study, we used data collected at the third examination (2005 - 2008) as baseline and that of the fourth examination (2008 - 2011) as follow-up. Of 12523 individuals who completed the third examination, 4920 were randomly selected for dietary assessment, based on their age and sex and 3687 completed the dietary assessment. Characteristics of participants who completed the dietary assessment were similar to those of the total population in the third examination of TLGS (17). Among the participants, 3133 individuals aged 18 - 74 years were selected for the current study. Participants with implausible values for total energy intake at baseline (n = 110), those with missing baseline (n = 82) or follow-up components of MetS information (n = 531) and those with diabetes (n = 169) were excluded. After exclusions, 2241 participants remained for the longitudinal study of the association between the Med-Diet scores and mean values of MetS components. For the analysis of the incidence of abnormalities in each MetS component, the number of participants was 1123 for high waist circumference (WC), 2045 for high fasting plasma glucose (FPG), 1530 for high triglycerides (TG), 817 for low high-density lipoprotein (HDL-C) and 1837 for high blood pressure (BP) after exclusion of prevalent abnormality in each component at baseline. For the analysis of the MetS incidence, 1661 participants remained after exclusion of individuals with MetS at baseline (n = 580).

3.1. Assessment of Adherence to the Mediterranean Diet

A valid and reliable food frequency questionnaire (FFQ) of 168 food items with standard serving sizes was used by trained dietitians to assess the usual food intake of individuals during 12 months before the examination (18, 19). The consumption frequency of each food item on a daily, weekly or monthly basis was converted to daily intakes;

portion sizes were then converted to grams using household measures. Dietary intakes at third examination were considered as dietary intake exposure at baseline.

Two scores were computed to determine the degree of adherence to the MedDiet. The Mediterranean diet score (MDS) was computed as defined by Trichopoulou et al. (20). Briefly, a value of 0 or 1 was assigned to each component using sex-specific median as cut-off. One point was assigned to individuals whose consumption of expected beneficial components (vegetable, legumes, fruits/nuts, cereals and fish) was equal or above the sex specific median and a value of zero was assigned for individuals whose consumption was below the median. For components presumed to be detrimental (meat and dairy products), 1 point was assigned if consumption was below the sex-specific median value and a value of zero otherwise. Because of the low consumption of olive oil in Iran, the ratio of unsaturated fat (monounsaturated plus polyunsaturated) to saturated was calculated for lipid intake; a value of 1 was assigned if this ratio was equal or above the sex specific median value and a value of zero was assigned for consumption below the median (21). Because of religious reasons, alcohol consumption is not usual or probably underreported in the Iranian population. Therefore, alcohol consumption was not considered as a food component. Thus, the total MDS scores ranged from zero (minimal adherence) to 8 (maximal adherence). Each food component was energy adjusted using the energy density method (g/1000 kcal) to determine the MDS score.

Adherence to the MedDiet was also assessed using sexspecific absolute values as the cut-off proposed by Sofi et al. for daily intakes of each of the above-mentioned food components (Sofi-MDS) (22). For each food component, the optimal numbers of change-points and the absolute values for these change-points were proposed. Briefly, values of zero or 2 were assigned to each components with one change point and zero or 1 or 2 to each component with 2 change-points. For presumed beneficial components, a score of 0, 1 or 2 was assigned to the lowest, middle and highest categories of intake. The scoring was inverted for the two presumed detrimental components. For this score, olive oil consumption was considered for lipid intake as a single dichotomized variable (yes/no). This score range was originally 0 to 16, but the possible maximum score in our study was 14, due to not considering alcohol consumption as a food component.

3.2. Other Measurements

Information on demographic variables, smoking status (yes/no), medical history and drug use were obtained using a pre-tested questionnaire. Participants who smoked daily or occasionally were called smokers and those who had never smoked were non-smokers.

Physical activity (PA) during the previous year was evaluated using the modified Kriska's PA questionnaire to obtain the frequency and the time spent on light, moderate, high and very high intensity activities according to a list of common activity of daily life (23, 24). Physical activity was expressed as metabolic equivalent minute per week (MET-min/wk).

Weight was measured to the nearest 100 g, wearing light clothes and without shoes. Height was measured to the nearest 0.5 cm in a standing position without shoes. WC was measured to the nearest 0.1 cm at the narrowest level over light clothing using an unscratched tape meter. BMI (Body Mass Index) was calculated as weight (Kg) divided by the square of the height (m²). BP was measured on the right arm in a sitting position, after a 15 minutes rest; the average of two such measurements considered as participants' blood pressure (16).

For biochemical measurements, blood samples were obtained after 12 - 14 hours overnight fasting. FPG and 2 hours-plasma glucose (2 hours-PG) post oral glucose tolerance test were measured by enzymatic colorimetric method with glucose oxidase. TG concentrations were measured by the enzymatic colorimetric method with glycerol phosphate oxidase and cholesterol esterase and cholesterol oxidase, respectively. HDL-C was measured after precipitation of apo-lipoprotein β with phosphotungstic acid. Analyses were performed using Pars Azmoon kits (Pars Azmoon Inc., Tehran, Iran) and a Selectra 2 auto-analyzer (Vital Scientific, Spankeren, The Netherlands). Inter- and intra-assay coefficients of variation (CVs) were 2.2% and 2.2% for FPG, 0.6% and 1.6% for TG, 0.5% and 2% for TC and HDL-C, respectively (15).

3.3. Metabolic Syndrome Ascertainment

MetS was defined according to the recent interim consensus as having three or more of the following criteria (1): Abdominal obesity (WC \geq 90 cm in both sexes (25)), high TG (\geq 1.7 mmol/L (150 mg/dL) or drug treatment for high triglycerides), low HDL-C (< 1.0 mmol/L (40 mg/dL) in men or < 1.3 mmol/L (50 mg/dL) in women or drug treatment), high blood pressure(SBP/DBP \geq 130/85 or antihypertensive drug treatment and high FPG (\geq 5.6 mmol/L (100 mg/dL) or drug treatment for elevated glucose).

3.4. Statistical Analysis

Participants were divided into tertiles according to their scores of adherence to the MedDiet. Baseline characteristics across tertiles of the diet score were compared using ANOVA for continuous variables and chi-square test for categorical variables. Based on existing literature and statistical tests, the following variables were considered as potential confounders: Age (continuous), sex (male/female), smoking (yes/no), physical activity (MET score in tertiles, or missing) at baseline, energy intake (continuous), BMI at baseline and BMI change in the 3-year follow-up. Means/geometric means (95% CI) for MetS components at follow-up examination across tertiles of the diet scores were determined using a general linear model, after adjusting for all the aforementioned confounders. FPG, TG and HDL were log-transformed to improve their normal distribution before analyses and then geometric means were reported. Participants who took any related medication were excluded from these analyses. In addition, odds (95% CI) of abnormalities incidence in each MetS components across tertiles of the diet scores were examined using logistic regression analysis after adjusting for potential confounders. In the analyses for incidence of abnormality in each component, prevalent events at baseline were excluded.

Odds ratio (OR) and 95 % CI of the MetS incidence across tertiles of the diet scores was examined using logistic regression analysis. Two models were constructed: Model 1 was adjusted for age and sex, and model 2 was further adjusted for smoking, physical activity, energy intake, BMI at baseline and BMI change. Tests for trend across dietary pattern scores were performed by assigning the median value of the tertiles to the respective categories and entering this as continuous variable into the models. Interactions between MedDiet scores and sex for the MetS incidence were tested by including cross products in our final model. All statistical analyses were conducted using SPSS (Version 15.0; Chicago, IL, USA) and P-values < 0.05 were considered significant.

4. Results

The mean age of our participants was 39.1 ± 13.6 years at baseline and 55.2% of them were females. The mean MDS was 4.4 (SD 1.5), ranged 0 - 8; 51.5 % had a MDS < 5. The mean Sofi-MDS was 7.3 (SD 2.1), ranged 2 - 14. According to Sofi-MDS, the proportion of the study population that attained the maximum score of 2 was highest for cereals (93.1% and 99.1% in female and male, respectively) and legumes (65.5% and 68.1% in females and males, respectively), and was lowest for vegetables (11.2% and 5.9% in females and males) and fish (31.2% and 24.6% in females and males) among the five beneficial food groups. For dairy products, 10.3% of females and 16.9% males had intakes of the proposed values of < 100 and \leq 150 g/day, respectively and therefore attained the score of 2. For meat and meat products, 95.3% of females (intake <130 g) and 93.9% of males (<140 g) attained the maximum score of 2. Baseline characteristics of participants across tertiles of Mediterranean dietary pattern scores are presented in Table 1. Participants with higher MDS score were older, less often women, had higher BMI and had lower dietary intakes of energy, saturated fatty acids, monounsaturated fatty acid, polyunsaturated fatty acid, calcium and magnesium. Participants with higher Sofi-MDS score were also older, more likely to be women and more active. A higher Sofi-MDS was associated with higher dietary intakes of energy, saturated fatty acids, monounsaturated fatty acid, polyunsaturated fatty acid, fiber, calcium and magnesium.

Figure 1 presents the association between the MedDiet scores and MetS components at follow-up across tertiles of the MedDiet scores. After adjusting for potential co-

variates, no significant differences were observed in the means of MetS components across tertiles of the Mediterranean dietary pattern scores at follow-up examinations (Figure 1). For the five components of MetS, the incidence of abnormalities identified during 3 years follow-up were 337 (30%) for high WC, 327 (16%) for high FPG, 221 (14.4%) for high TG, 96 (11.8%) for low HDL-C and 320 (17.4%) for high BP. There were no significant differences in the odds of 3-year abnormality in each of the MetS components across tertiles of the MedDiet scores (Table 2).

Table 1. Baseline Characteristics Across Tertiles of Dietary Pattern Score^a

TiT2T3PValue bT1T2T3PValue bScore cut-off0 - 345 - 82 - 67 - 89 - 14Number5865681087902789550Age, y363 (13.3)37.9 (13.0)41.3 (13.8)< 0.00138.4 (13.6)39.1 (13.8)40.4 (13.2)0.024Sex (female), %65.256.249.4< 0.00153.851.563.6< 0.001Smokers11.917.114.20.04415.114.213.30.630BMl, kg/m ² 26.5 (5.2)26.4 (4.8)27.1 (4.8)0.00626.5 (4.9)26.5 (4.9)26.5 (5.9)< 0.001Physical activity, Metmin/week CC33.534.732.736.834.526.3< 0.001126 33.932.733.13.932.731.630.933.7< 0.001261032.732.734.230.933.737.3< 0.00126.6 (7.5)58.0 (8.9)< 0.001261032.732.734.210.0120.6 (7.5)58.0 (8.9)59.0 (8.9)< 0.001261032.732.734.210.0126.6 (7.5)58.0 (8.9)59.0 (8.9)< 0.001261032.732.734.210.0120.6 (7.5)58.0 (8.9)59.0 (8.9)< 0.001261032.732.734.210.0113.6 (7.7)38.0 (8.9)50.0 (8.0)39.0 (8.0)< 0.001261032	Characteristics		MI	DS	•	Sofi-MDS				
Score cut-off0 - 345 - 82 - 67 - 89 - 14Number5865681087902789550Age, y363 (13.3)37.9 (13.0)41.3 (13.8)< 0.00138.4 (13.6)39.1 (13.8)40.4 (13.2)0.024Sex (female), %65.256.249.4< 0.00153.851.563.6< 0.001Smokers11.917.114.20.04415.114.213.30.630BMI, kg/m²26.5 (5.2)26.4 (4.8)27.1 (4.8)0.00626.5 (4.9)26.5 (5.9)26.5 (5.9)26.5 (5.9)Physical activity, Met-min/wete '-0.935-0.03330.6 (5.9)26.5 (5.9)26.5 (5.9)26.5 (5.9)126 - 61033.534.732.733.634.231.936.526.3 (5.9)26.0 (5.1)261633.932.732.733.132.231.935.737.3-Stenzy indake, Kcal/day2532 (81)2308 (79)2164 (70.5)26.3 (7.5)28.3 (6.9)58.9 (6.94)<0.001Carbohydrate, % of total energy33.5 (7.7)31.6 (7.7)35.6 (7.5)58.3 (6.8)58.9 (6.94)<0.001Protein, % of total energy33.5 (7.7)31.6 (7.7)35.6 (7.5)36.4 (5.5)36.4 (7.5)30.4 (7.5)<0.001At y of total energy33.5 (7.7)31.6 (7.7)28.6 (3.9)35.2 (5.6)30.4 (5.7)<0.001At y of total energy33.5 (7.7)31.6 (7.7)28.6 (3.9) <th></th> <th>T1</th> <th>T2</th> <th>T3</th> <th>P Value b</th> <th>T1</th> <th>T2</th> <th>T3</th> <th>P Value^b</th>		T1	T2	T3	P Value b	T1	T2	T3	P Value ^b	
Number5865681087902789550Age, y363 (13.3)37.9 (13.0)41.3 (13.8)<0.00138.4 (13.6)39.1 (13.8)40.4 (13.2)0.024Sex (female), %65.256.249.4<0.00153.851.563.6<0.011Smokers11.917.114.20.04415.114.213.30.630BMI, kg/m ² 26.5 (5.2)26.4 (4.8)27.1 (4.8)0.00626.5 (4.9)26.7 (4.9)26.5 (5.0)<0.011Physical activity, Met-min/week C0.33.534.732.736.834.526.312633.534.732.736.834.526.3> 61032.732.733.132.231.935.5> 61032.732.734.230.933.537.3Carbohydrate, Kcal/day2532 (81)2308 (779)2164 (705)40.012065 (716)2347 (72)2604 (73)<0.001Grabohydrate, % of total energy13.9 (2.77)31.6 (2.50)35.0 (2.70)35.3 (5.75)58.3 (6.89)58.9 (6.94)<0.001Fat, % of total energy35.5 (7.77)31.6 (7.17)29.8 (6.39)25.0 (1.0)25.7 (2.0)32.6 (2.1)30.4 (6.1)<0.001Saturated fat, g/d34.5 (24.9)26.9 (1.0)25.6 (1.0)25.0 (1.0)25.8 (1.2)25.6 (1.0)32.6 (7.75)30.6 (5.5)30.4 (6.1)<0.001Fat, % of total	Score cut-off	0-3	4	5 - 8		2 - 6	7-8	9 - 14		
Age, y363 (13.3)37.9 (13.0)41.3 (13.8)<0.001	Number	586	568	1087		902	789	550		
Sex (female), %65.256.249.4<0.001	Age, y	36.3 (13.3)	37.9 (13.0)	41.3 (13.8)	< 0.001	38.4 (13.6)	39.1 (13.8)	40.4 (13.2)	0.024	
Smokers11.917.114.20.04415.114.213.30.630BMI, kg/m²265 (5.2)26.4 (4.8)27.1 (4.8)0.00626.5 (4.9)26.7 (4.9)26.5 (5.0)< 0.001	Sex (female), %	65.2	56.2	49.4	< 0.001	53.8	51.5	63.6	< 0.001	
BMI, kg/m²265. (5.2)26.4 (4.8)27.1 (4.8)0.00626.5 (4.9)26.7 (4.9)26.5 (5.0)< 0.001	Smokers	11.9	17.1	14.2	0.044	15.1	14.2	13.3	0.630	
Physical activity, Met-min/week ^C 0.9350.003<12633.534.732.736.834.526.3126 - 61033.932.733.132.231.936.5-> 61032.732.734.230.933.537.3-Energy intake, Kcal/day2532 (811)2308 (779)2164 (705)<0.0012065 (716)2347 (762)2604 (739)<0.001Carbohydrate, % of total energy54.4 (7.62)57.0 (7.19)59.7 (6.58)0.00156.3 (7.55)58.3 (6.89)58.9 (6.94)<0.001Protein, % of total energy13.9 (2.74)13.6 (2.50)13.5 (2.28)<0.00113.5 (2.56)13.6 (2.41)13.9 (2.37)0.004Fat, % of total energy33.5 (7.77)31.6 (7.17)29.8 (6.39)<0.00132.3 (7.55)30.6 (6.55)30.4 (6.71)<0.001Saturated fat, g/d34.5 (24.9)26.9 (11.0)22.6 (9.2)<0.00125.7 (2.0.4)26.8 (12.0)30.9 (12.8)<0.001Monounsaturated fat, g/d34.4 (10.2)16.9 (8.50)15.7 (7.55)<0.00115.6 (8.39)16.6 (8.23)30.9 (12.8)<0.001Polyunsaturated fat, g/d18.4 (10.2)16.9 (8.50)15.7 (7.55)<0.00115.6 (8.39)16.6 (8.23)18.5 (9.19)<0.001Dietary fiber, g/d36.4 (23.2)38.3 (22.9)38.9 (20.5)0.07631.7 (21.0)39.8 (12.6)40.0 (20.6)<0.001Dietary fiber, g/d1432 (666)1225 (517)1144 (534)<0.0011100	BMI, kg/m ²	26.5 (5.2)	26.4 (4.8)	27.1 (4.8)	0.006	26.5 (4.9)	26.7(4.9)	26.5 (5.0)	< 0.001	
<126	Physical activity, Met-min/week ^C				0.935				0.003	
126 - 61033.932.733.132.231.936.5> 61032.732.734.230.933.537.3Energy intake, Kcal/day2532 (81)2308 (779)2164 (705)<0.0012065 (716)2347 (762)2604 (739)<0.001Carbohydrate, % of total energy54.4 (7.62)57.0 (7.19)59.7 (6.58)0.00156.3 (7.75)58.3 (6.89)58.9 (6.94)<0.001Protein, % of total energy13.9 (2.74)13.6 (2.50)13.5 (2.28)<0.00113.5 (2.56)13.6 (2.41)13.9 (2.37)0.004Fat, % of total energy33.5 (7.77)31.6 (7.17)29.8 (6.39)<0.00132.3 (7.75)30.6 (6.55)30.4 (6.71)<0.001Saturated fat, g/d34.5 (24.9)26.9 (11.0)22.6 (9.2)<0.00125.7 (20.4)26.8 (12.3)28.6 (12.1)0.004Monounsaturated fat, g/d32.4 (14.6)28.0 (12.0)25.0 (10.2)<0.00125.8 (12.2)27.6 (11.8)30.9 (12.8)<0.001Polyunsaturated fat, g/d18.4 (10.2)16.9 (8.50)15.7 (7.55)<0.00115.6 (8.39)16.6 (8.23)18.5 (9.19)<0.001Dietary fiber, g/d36.4 (23.2)38.3 (22.9)38.9 (20.5)0.07631.7 (21.0)39.8 (21.6)46.0 (20.6)<0.001Calcium, mg/d1432 (666)1225 (517)1144 (534)<0.0011100 (465)1245 (563)1461 (694)<0.001	<126	33.5	34.7	32.7		36.8	34.5	26.3		
> 610 32.7 32.7 34.2 30.9 33.5 37.3 Energy intake, Kcal/day 2532 (81) 2308 (779) 2164 (705) <0.001 2065 (716) 2347 (762) 2604 (739) <0.001 Carbohydrate, % of total energy 54.4 (7.62) 57.0 (7.19) 59.7 (6.58) 0.001 56.3 (7.75) 58.3 (6.89) 58.9 (6.94) <0.001 Protein, % of total energy 13.9 (2.74) 13.6 (2.50) 13.5 (2.28) <0.001 13.5 (2.56) 13.6 (2.41) 13.9 (2.37) 0.004 Fat, % of total energy 33.5 (7.77) 31.6 (7.17) 29.8 (6.39) <0.001 32.3 (7.5) 30.6 (5.55) 30.4 (6.71) <0.004 Saturated fat, g/d 34.5 (24.9) 26.9 (1.0) 22.6 (9.2) <0.001 25.7 (20.4) 26.8 (12.3) 28.6 (12.1) 0.004 Monounsaturated fat, g/d 32.4 (14.6) 28.0 (12.0) 25.0 (10.2) <0.001 15.6 (8.39) 16.6 (8.23) 18.5 (9.19) <0.001 Polyunsaturated fat, g/d 18.4 (10.2) 16.9 (8.50) 15.7 (7.55) <0.001 15.6 (8.39)	126 - 610	33.9	32.7	33.1		32.2	31.9	36.5		
Energy intake, Kcal/day2532 (811)2308 (779)2164 (705)<0.0012065 (716)2347 (762)2604 (739)<0.001Carbohydrate, % of total energy54.4 (7.62)57.0 (7.19)59.7 (6.58)0.00156.3 (7.75)58.3 (6.89)58.9 (6.94)<0.001Protein, % of total energy13.9 (2.74)13.6 (2.50)13.5 (2.28)<0.00113.5 (2.56)13.6 (2.41)13.9 (2.37)0.004Fat, % of total energy33.5 (7.77)31.6 (7.17)29.8 (6.39)<0.00132.3 (7.75)30.6 (6.55)30.4 (6.71)<0.001Saturated fat, g/d34.5 (24.9)26.9 (11.0)22.6 (9.2)<0.00125.7 (20.4)26.8 (12.3)28.6 (12.1)0.004Monounsaturated fat, g/d32.4 (14.6)28.0 (12.0)25.0 (10.2)<0.00125.8 (12.2)27.6 (11.8)30.9 (12.8)<0.001Polyunsaturated fat, g/d18.4 (10.2)16.9 (8.50)15.7 (7.55)<0.00115.6 (8.39)16.6 (8.23)18.5 (9.19)<0.001Dietary fiber, g/d36.4 (23.2)38.3 (22.9)38.9 (20.5)0.07631.7 (21.0)39.8 (21.6)46.0 (20.6)<0.001Calcium, mg/d1432 (666)1225 (517)1144 (534)<0.0011100 (465)1245 (563)1461 (694)<0.001	> 610	32.7	32.7	34.2		30.9	33.5	37.3		
Carbohydrate, % of total energy54.4 (7.62)57.0 (7.19)59.7 (6.58)0.00156.3 (7.75)58.3 (6.89)58.9 (6.94)<0.001	Energy intake, Kcal/day	2532 (811)	2308 (779)	2164 (705)	< 0.001	2065 (716)	2347 (762)	2604 (739)	< 0.001	
Protein,% of total energy 13.9 (2.74) 13.6 (2.50) 13.5 (2.28) < 0.001	Carbohydrate, % of total energy	54.4 (7.62)	57.0 (7.19)	59.7(6.58)	0.001	56.3 (7.75)	58.3 (6.89)	58.9 (6.94)	< 0.001	
Fat, % of total energy33.5 (7.77)31.6 (7.17)29.8 (6.39)<0.001	Protein, % of total energy	13.9 (2.74)	13.6 (2.50)	13.5 (2.28)	< 0.001	13.5 (2.56)	13.6 (2.41)	13.9 (2.37)	0.004	
Saturated fat, g/d34.5 (24.9)26.9 (11.0)22.6 (9.2)< 0.001	Fat, % of total energy	33.5 (7.77)	31.6 (7.17)	29.8 (6.39)	< 0.001	32.3 (7.75)	30.6 (6.55)	30.4 (6.71)	< 0.001	
Monounsaturated fat, g/d32.4 (14.6)28.0 (12.0)25.0 (10.2)<0.001	Saturated fat, g/d	34.5 (24.9)	26.9 (11.0)	22.6 (9.2)	< 0.001	25.7(20.4)	26.8 (12.3)	28.6 (12.1)	0.004	
Polyunsaturated fat, g/d 18.4 (10.2) 16.9 (8.50) 15.7 (7.55) < 0.001	Monounsaturated fat, g/d	32.4 (14.6)	28.0 (12.0)	25.0 (10.2)	< 0.001	25.8 (12.2)	27.6 (11.8)	30.9 (12.8)	< 0.001	
Dietary fiber, g/d 36.4 (23.2) 38.3 (22.9) 38.9 (20.5) 0.076 31.7 (21.0) 39.8 (21.6) 46.0 (20.6) < 0.001	Polyunsaturated fat, g/d	18.4 (10.2)	16.9 (8.50)	15.7 (7.55)	< 0.001	15.6 (8.39)	16.6 (8.23)	18.5 (9.19)	< 0.001	
Calcium, mg/d 1432 (666) 1225 (517) 1144 (534) < 0.001 1100 (465) 1245 (563) 1461 (694) < 0.001	Dietary fiber, g/d	36.4 (23.2)	38.3 (22.9)	38.9 (20.5)	0.076	31.7 (21.0)	39.8 (21.6)	46.0 (20.6)	< 0.001	
	Calcium, mg/d	1432 (666)	1225 (517)	1144 (534)	< 0.001	1100 (465)	1245 (563)	1461(694)	< 0.001	
Magnesium, mg/d 394 (156) 374 (146) 371 (144) < 0.001	Magnesium, mg/d	394 (156)	374 (146)	371 (144)	< 0.001	325 (130)	384 (139)	456 (152)	< 0.001	

Abbreviation: MDS, the Mediterranean diet score.

 P-Value based on ANOVA and chi-square test. ^C There were 287 missing data on physical activity.

Table 2. Baseline Mediterranean diet score related to 3-year incidence of abnormalities in each component of metabolic syndrome in the study population ^a

Mediterranean diet scores											
Diet Score	Total T1			T2			T3			P-trend	
		n (%) ^b	OR	95%CI	n (%) ^b	OR	95%CI	n (%) ^b	OR	95%CI	-
MDS											
High WC ^C	1123	103 (30)	1.00	ref	87 (28.8)	0.86	0.54, 1.38	147 (30.8)	0.74	0.48, 1.13	0.56
High FPG ^d	2045	74 (13.7)	1.00	ref	82 (15.5)	1.01	0.77, 1.57	171 (17.5)	1.01	0.73, 1.39	0.55
High TG ^e	1530	63 (14.4)	1.00	ref	48 (12.3)	0.74	0.48, 1.12	110 (15.7)	0.81	0.56, 1.17	0.43
Low HDL ^f	817	32 (14.3)	1.00	ref	25 (12.6)	0.99	0.55, 1.78	39 (9.9)	0.82	0.48, 1.40	0.22
High BP ^g	1837	85 (17.0)	1.00	ref	65 (13.6)	0.70	0.48,1.02	170 (19.8)	0.89	0.64, 1.22	0.95
Sofi-MDS											
High WC	1123	128 (26.9)	1.00	ref	108 (29.3)	1.07	0.71, 1.62	101 (36.1)	0.84	0.52, 1.33	0.82
High FPG	2045	125 (15.1)	1.00	ref	102 (14.2)	0.82	0.61, 1.10	100 (20.0)	1.23	0.89, 1.70	0.40
High TG	1530	89 (14.2)	1.00	ref	84 (15.8)	0.95	0.67, 1.34	48 (13.0)	0.77	0.51, 1.17	0.79
Low HDL	817	34 (10.0)	1.00	ref	37 (12.8)	1.15	0.68, 1.96	25 (13.2)	1.09	0.60, 1.99	0.16
High BP	1837	126 (16.7)	1.00	ref	121 (19.1)	1.06	0.77, 1.45	73 (16.2)	0.82	0.56, 1.20	0.17

^a Adjusted for age, sex, energy Intake, physical activity, smoking, BMI baseline and BMI Change in 3 years follow-up. Abbreviations: WC, waist circumference; FPG, fasting plasma glucose; TG, Triglycerides; HDL-C, HDL cholesterol; BP, blood pressure; ref, referent category. Number of new cases for each component by tertiles.

^c WC \ge 90 cm for both sexes. ^d FPG \ge 5.6 mmol/L or drug treatment for elevated glucose.

 e_{f} TG \geq 1.7 mmol/L or drug treatment for high triglycerides.

f HDL-C (<1.0 mmol/L in men or <1.3 mmol/L) in women or drug treatment.

^g Systolic \geq 130 and/or diastolic \geq 85 mmHg or antihypertensive drug treatment.





Values are adjusted mean/geometric means (95% CI). Values are adjusted for age, sex, energy intake, physical activity, smoking, BMI baseline and BMI change in 3-year follow-up. 1 n = 2241. 2 n = 2216 who were not treated by oral hypoglycemia or insulin medications. 3 n = 2069 who were not treated by cholesterol-lowering medications. 4 n = 2055 who were not treated by hypertension-lowering medications.

A total of 246 incident MetS cases were identified during the 3-year follow-up among 1661 participants, free of metabolic syndrome at baseline. The adjusted odds ratio (OR) of MetS incidence did not differ significantly in participants with the highest tertile of the MDS or Sofi-MDS compared to those in the lowest categories in both age and sex adjusted model and the multivariable adjusted model (Figure 2). There were no significant interactions by sex in the relations between MDS (P = 0.52) or Sofi-MDS (P = 0.12) and incident MetS.



Figure 2. Odds of 3-Year Incidence of Metabolic Syndrome Across Tertiles of the Mediterranean Diet Scores

5. Discussion

In this prospective study conducted on Iranian adults without type 2 diabetes, greater adherence to the MedDiet was not associated with either lower MetS components or lower incidence of metabolic abnormalities, after 3 years of follow-up. In addition, we did not find any significant associations between the two scores used to assess adherence to this pattern and the 3-year MetS incidence, after adjusting for potential confounders.

Previous prospective studies consistently report an inverse association between adherence to the MedDiet and MetS incidence, though the strength of the association was varied (7-9). However, previous findings on the association between MedDiet and MetS components have been contradictory (7-9, 11, 12). In a Spanish population, adherence to the MedDiet according to MDS was related to 80% lower risk of MetS after a 6-year follow-up, but the score was only related to WC (mean difference between the highest and lowest tertiles: 0.5 cm, p-trend: 0.04) (7). In a USA population, participants with higher adherence to the MedDiet according to the Mediterranean style-dietary pattern score (MSDPS) had lowest cumulative incidence of MetS over 7 years of follow-up. In that study, WC. FPG, TG and HDL-C were significantly related to the MSDPS (8). The last prospective study conducted among French adults showed that higher adherence to the MedDiet was associated with 50% and 53% lower MetS incident after 6 years of follow-up based on MDS score and a revised Mediterranean score (MED) respectively, while according to the MSDPS the inverse association became non-significant after adjusting for potential confounders (9). While MSDP was related to most MetS components in a USA population, this index in the French study was related only to HDL-C. However, MED score was associated to WC, SBP, TG and HDL-C (9). Some discrepancies between the studies could be due to the score used to evaluate adherence to the MedDiet that can affect strength and the significance of the associations (6, 26). A previous prospective study conducted in the TLGS also found no significant association between MDS and WC after 6.7 years of follow-up (27).

Different indexes were developed to assess the adherence to the MedDiet with varying in the components included, the weight given to each component and the scoring system used (26). Using MDS as suggested by Trichopoulou et al. (20) with some modification, 48.5% of our participants had the highest degree of adherence (Tertile 3). Since the scoring system for calculating MDS is based on sample-specific median consumption, we considered the absolute values for each component as proposed by Sofi et al. in the second scoring of the MedDiet (22). According to Sofi et al., the actual amounts for each food component should be consumed to describe adherence to the MedDiet (22). Based on the score, only 24.5% of our participants had the highest adherence. Adherence to the MedDiet increased with age in both the scores used. Intakes of energy, macronutrients and nutrients across the tertiles of the diet scores were different, because calculation of the first score was based on energyadjusted median of each component, while for Sofi-MDS, absolute values were used. None of these two scores was associated with MetS and its components in our study, which could suggest that something beyond quantitative differences in the intakes of each component in our population, compared to the Mediterranean countries, may lead to non-significant associations observed in our study between the pattern and MetS.

Cereals as a beneficial food item include both refined and whole cereals in determination of the degree adherence to the MedDiet, although in the traditional MedDiet, cereals were largely unrefined. The effects of refined- and whole-cereals on health may be distinct and this is one of the concerns about using the MedDiet scores (28, 29). More than 90% of our population met the proposed values intake of cereals according to the Sofi-MDS. However, in an Iranian population, white rice and refined cereals constituted the major part of daily cereals consumption. Previous studies on the association between white rice and MetS provided inconsistent findings despite most investigations suggesting an increased risk of developing diabetes and cardio metabolic risk factors with increasing rice consumption (30). However, the non-significant association of white rice consumption and the risk of MetS in Iranian participants on high-fiber diet suggest that the possible adverse effects of white rice on metabolic outcomes could be, in part, due to low consumption of fruit and vegetable intake (30).

The daily median intake of fish in our population was lower than the median intake in a Greek population (6.4 vs. 18.8 g/day for female; 7.1 vs. 23.7 g/day for male). According to Sofi-MDS, 31.2% of women and 24.6% of men consumed the highest value intake of fish and seafood. In addition to variation in quantity of fish intake, differences in the type of fish consumed and the way of cooking between the Mediterranean and non-Mediterranean countries can affect the amount of n-3 PUFA intake (10). In Mediterranean countries, frying fish with olive oil, especially virgin olive oil, is the most common way of preparing fish, which has been found to increase the nutritional benefits of fish because of the absorption of antioxidants phenolics, terpenic acids and vitamin E. In Iran, frying fish with sunflower or corn oil is the most common method of preparing fish, which has been shown to reduce n-3 and increase n-6 fatty acid content of fish (10).

While using olive oil for cooking and salad dressing daily is common in the Mediterranean countries, few people in Iran consume olive oil. Therefore, we considered the ratio of unsaturated fat to SFA instead of median intake of olive oil in the first score (21). However, because of high consumption of other vegetable oils, including sunflower and corn oils for cooking in Iran, there is higher consumption of PUFA, especially n-6 than n-3 PUFA and MUFA. According to the second score, Sofi-MDS, only 4.8% of our participants were categorized as daily users of olive oil and those whose intake of olive oil was still low with a mean consumption of 18 g/day. Therefore, most of MUFA intake in our populations is from animal fat rather than olive oil. Olive oil, especially virgin olive oil, as a key component of the MedDiet has a fundamental effect on prevention of chronic diseases because of not only high content of MUFA, but also existence of its nonsaponifiable fraction (10).

It has been well explained by Hoffman and Gerber that nutritional benefits or detriments that different populations receive from consuming each component of the MedDiet can vary and cannot be assessed simply by absolute levels of their consumptions (10). Differences in availability of foods, preferences for eating of foods in each food groups, processing and preparation of foods that influence the composition of a food between the Mediterranean and non-Mediterranean countries can also affect the overall health benefits of the MedDiet in non-Mediterranean countries (10). Most extensive epidemiological evidence supporting the beneficial effects of the MedDiet has been documented in the Mediterranean countries (5, 6). In addition, according to the results of a meta-analysis, the effect of the MedDiet on metabolic syndrome and its components has been more prominent in Mediterranean countries (5). Therefore, it seems that the protective effect of the MedDiet against chronic diseases could be attributed to the diet and other eating behaviors such as the time of eating, the order of courses in each meal and the meal patterns or other potentially confounders such as genetics and sun exposure (10, 31).

In this study, we adjusted for BMI change over 3 years follow-up to control the confounding effect of change in BMI on the associations between MedDiet and MetS incidence. However, BMI change is likely to mediate the effect of MedDiet on MetS incidence. Some previous studies suggested an inverse association between MedDiet and the risk of MetS independent of BMI and BMI change over time (8, 9). However, in this study we could not find any significant associations before (age and sex adjusted model) and after adjustment for BMI change.

Prospective design, using recently proposed index considering the absolute amount of each food components in addition to calculating the score according to the sexspecific median intake to ascertain conformity to the MedDiet, and using an FFQ specially developed and validated in our population are strengths of our study. However, our study had some limitations that may explain lack of association. First, scoring participants according to the MedDiet in an Iranian population might be inefficient, because the dietary patterns are very different from those living in Mediterranean countries. Another limitation was possible concerns about using an FFQ to measure food consumption, which may increase the possibility of overestimation in consumption of healthy food items and underestimation in consumption of unhealthy food items (31).

In conclusion, we could not find any significant associations between adherence to the MedDiet, according to MDS and Sofi-MDS and MetS components and MetS incidence after 3 years of follow-up in an Iranian population. More studies in non-Mediterranean countries are needed to investigate the applicability of the MedDiet and its benefits to the prevention of metabolic abnormalities.

Acknowledgements

We express our appreciation to the participants of TLGS for their collaboration and to the entire TLGS staff. This study was supported by a grant by the research institute of endocrine sciences, Shahid Beheshti university of medical sciences, Tehran, Iran. The authors wish to acknowledge Ms. Niloofar Shiva for critical editing of English grammar and syntax of the manuscript. There are no conflicts of interest.

Authors' Contributions

Statistical analysis and interpretation of data: Nazanin Moslehi and Hessameddin Mahmoudof. Drafting of the manuscript: Nazanin Moslehi. Collection of data: Mahbubeh Sadeghi. Providing advice and revision of the manuscript: Parvin Mirmiran and Fereidoun Azizi. All authors were involved in the study design and approved the final version of manuscript.

References

- Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*. 2009;**120**(16):1640–5.
- Shin JA, Lee JH, Lim SY, Ha HS, Kwon HS, Park YM, et al. Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness. J Diabetes Investig. 2013;4(4):334–43.
- Sofi F, Abbate R, Gensini GF, Casini A. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. *Am J Clin Nutr.* 2010;92(5):1189–96.
- Giugliano D, Esposito K. Mediterranean diet and metabolic diseases. Current Opinion Internal Med. 2008;7(2):149–54.
- Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol. 2011;57(11):1299–313.
- Esposito K, Kastorini CM, Panagiotakos DB, Giugliano D. Mediterranean diet and metabolic syndrome: an updated systematic review. *Rev Endocr Metab Disord*. 2013;14(3):255–63.
- Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A, Basterra-Gortari FJ, Nunez-Cordoba JM, Martinez-Gonzalez MA. Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort. *Diabetes Care*. 2007;**30**(11):2957–9.
- Rumawas ME, Meigs JB, Dwyer JT, McKeown NM, Jacques PF. Mediterranean-style dietary pattern, reduced risk of metabolic syndrome traits, and incidence in the Framingham Offspring Cohort. *Am J Clin Nutr.* 2009;**90**(6):1608-14.
- Kesse-Guyot E, Ahluwalia N, Lassale C, Hercberg S, Fezeu L, Lairon D. Adherence to Mediterranean diet reduces the risk of metabolic syndrome: a 6-year prospective study. *Nutr Metab Cardiovasc Dis.* 2013;23(7):677–83.
- Hoffman R, Gerber M. Evaluating and adapting the Mediterranean diet for non-Mediterranean populations: a critical appraisal. Nutr Rev. 2013;71(9):573-84.
- Alvarez Leon E, Henriquez P, Serra-Majem L. Mediterranean diet and metabolic syndrome: a cross-sectional study in the Canary Islands. *Public Health Nutr.* 2006;9(8A):1089–98.
- 12. Babio N, Bullo M, Basora J, Martinez-Gonzalez MA, Fernandez-Ballart J, Marquez-Sandoval F, et al. Adherence to the Mediterranean diet and risk of metabolic syndrome and its components. *Nutr Metab Cardiovasc Dis.* 2009;**19**(8):563-70.
- Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. *Diabetes Res Clin Pract.* 2007;77(2):251–7.
- 14. Zabetian A, Hadaegh F, Sarbakhsh P, Azizi F. Weight change and

incident metabolic syndrome in Iranian men and women; a 3 year follow-up study. *BMC Public Health*. 2009;**9**:138.

- Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1). Soz Praventivmed. 2002;47(6):408–26.
- Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. *Trials*. 2009;**10**:5.
- Hosseini-Esfahani F, Jessri M, Mirmiran P, Bastan S, Azizi F. Adherence to dietary recommendations and risk of metabolic syndrome: Tehran Lipid and Glucose Study. *Metabolism*. 2010;59(12):1833–42.
- 18. Mirmiran P, Esfahani FH, Mehrabi Y, Hedayati M, Azizi F. Reliability and relative validity of an FFQ for nutrients in the Tehran lipid and glucose study. *Public Health Nutr.* 2010;**13**(5):654–62.
- Esfahani FH, Asghari G, Mirmiran P, Azizi F. Reproducibility and relative validity of food group intake in a food frequency questionnaire developed for the Tehran Lipid and Glucose Study. J Epidemiol. 2010;20(2):150–8.
- Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med. 2003;348(26):2599–608.
- Trichopoulou A, Orfanos P, Norat T, Bueno-de-Mesquita B, Ocke MC, Peeters PH, et al. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. *BMJ*. 2005;330(7498):991.
- Sofi F, Abbate R, Gensini GF, Casini A, Trichopoulou A, Bamia C. Identification of change-points in the relationship between food groups in the Mediterranean diet and overall mortality: an 'a posteriori' approach. *Eur J Nutr.* 2012;**51**(2):167–72.
- Kriska AM, Knowler WC, LaPorte RE, Drash AL, Wing RR, Blair SN, et al. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. *Diabetes Care*. 1990;13(4):401-11.
- 24. Momenan AA, Delshad M, Sarbazi N, Rezaei Ghaleh N, Ghanbarian A, Azizi F. Reliability and validity of the Modifiable Activity Questionnaire (MAQ) in an Iranian urban adult population. *Arch Iran Med.* 2012;**15**(5):279–82.
- Azizi F, Khalili D, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, et al. Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity. *Arch Iran Med.* 2010;13(3):243–4.
- 26. Mila-Villarroel R, Bach-Faig A, Puig J, Puchal A, Farran A, Serra-Majem L, et al. Comparison and evaluation of the reliability of indexes of adherence to the Mediterranean diet. *Public Health Nutr.* 2011;**14**(12A):2338–45.
- 27. Asghari G, Mirmiran P, Rashidkhani B, Asghari-Jafarabadi M, Mehran M, Azizi F. The association between diet quality indices and obesity: Tehran Lipid and Glucose Study. *Arch Iran Med.* 2012;**15**(10):599–605.
- Buckland G, Agudo A, Lujan L, Jakszyn P, Bueno-de-Mesquita HB, Palli D, et al. Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. *Am J Clin Nutr.* 2010;91(2):381–90.
- 29. Dominguez LJ, Bes-Rastrollo M, de la Fuente-Arrillaga C, Toledo E, Beunza JJ, Barbagallo M, et al. Similar prediction of total mortality, diabetes incidence and cardiovascular events using relativeand absolute-component Mediterranean diet score: the SUN cohort. *Nutr Metab Cardiovasc Dis.* 2013;**23**(5):451–8.
- Bahadoran Z, Mirmiran P, Delshad H, Azizi F. White rice consumption is a risk factor for metabolic syndrome in Tehrani adults: a prospective approach in Tehran Lipid and Glucose Study. Arch Iran Med. 2014;17(6):435–40.
- Sanchez-Villegas A, Martinez JA, De Irala J, Martinez-Gonzalez MA. Determinants of the adherence to an "a priori" defined Mediterranean dietary pattern. *Eur J Nutr.* 2002;41(6):249–57.